EPHX2 and hypertensive disorder: The inhibition of sEH demonstrates a promising approach to treat various diseases, including hypertension (Imig et al., 2005; Anandan et al., 2011), inflammation (Davis et al., 2011; Bastan et al., 2018), diabetes (Lorthioir et al., 2012; Hu et al., 2017), neuropathic pain (Hammock et al., 2011; McReynolds et al., 2016; Wagner K. et al., 2017; Wagner K. M. et al., 2017), and central nervous system (CNS) disorders (Simpkins et al., 2009; Ren et al., 2016; Zarriello et al., 2018).